Stock DXB DIMERIX LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dimerix Limited

Equities

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
0.32 AUD -4.48% Intraday chart for Dimerix Limited +10.34% +56.10%
Apr. 22 Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter MT
Apr. 19 Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target MT

Valuation

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Capitalization 1 14.73 13.5 69.21 38.61 38.5 24.06
Enterprise Value (EV) 1 8.445 9.935 62.52 38.45 28.95 22.03
P/E ratio -3.3 x -4.67 x -13.4 x -6.06 x -3.37 x -1.46 x
Yield - - - - - -
Capitalization / Revenue 17.4 x 9.33 x 29.6 x 8.7 x 5.96 x 2.68 x
EV / Revenue 9.99 x 6.86 x 26.7 x 8.66 x 4.48 x 2.45 x
EV / EBITDA -2.55 x -3.45 x -13.7 x -5.93 x -2.76 x -1.59 x
EV / FCF -4.3 x -6.06 x -19.9 x -9.1 x -2.91 x -2.9 x
FCF Yield -23.2% -16.5% -5.03% -11% -34.4% -34.5%
Price to Book 2.15 x 3.21 x 8.92 x 26.3 x 2.67 x 4.03 x
Nbr of stocks (in thousands) 155,049 158,799 197,749 197,999 320,874 388,059
Reference price 2 0.0950 0.0850 0.3500 0.1950 0.1200 0.0620
Announcement Date 8/30/18 8/29/19 8/26/20 8/15/21 8/28/22 8/29/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.8453 1.447 2.341 4.44 6.466 8.984
EBITDA 1 -3.313 -2.882 -4.576 -6.479 -10.49 -13.84
EBIT 1 -3.32 -2.886 -4.577 -6.488 -10.49 -13.84
Operating Margin -392.73% -199.41% -195.54% -146.15% -162.25% -154.05%
Earnings before Tax (EBT) 1 -3.32 -2.886 -4.494 -6.372 -10.49 -13.8
Net income 1 -3.32 -2.886 -4.494 -6.372 -10.49 -13.8
Net margin -392.73% -199.41% -191.98% -143.52% -162.25% -153.64%
EPS 2 -0.0288 -0.0182 -0.0262 -0.0322 -0.0356 -0.0424
Free Cash Flow 1 -1.962 -1.639 -3.148 -4.228 -9.964 -7.604
FCF margin -232.16% -113.22% -134.47% -95.22% -154.1% -84.64%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/30/18 8/29/19 8/26/20 8/15/21 8/28/22 8/29/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 6.28 3.56 6.69 0.16 9.56 2.03
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.96 -1.64 -3.15 -4.23 -9.96 -7.6
ROE (net income / shareholders' equity) -70% -52.2% -75.1% -138% -132% -135%
ROA (Net income/ Total Assets) -40.9% -29.6% -37.3% -40.9% -50.6% -50.5%
Assets 1 8.109 9.764 12.04 15.56 20.73 27.33
Book Value Per Share 2 0.0400 0.0300 0.0400 0.0100 0.0400 0.0200
Cash Flow per Share 2 0.0400 0.0200 0.0400 0.0300 0.0300 0.0200
Capex 1 0 0.01 - 0.01 0.01 0
Capex / Sales 0.42% 0.48% - 0.22% 0.16% 0.03%
Announcement Date 8/30/18 8/29/19 8/26/20 8/15/21 8/28/22 8/29/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DIMERIX LIMITED Stock Dimerix Limited
+56.10% 115M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DXB Stock
  4. Financials Dimerix Limited